Lugano, Switzerland, 14 June 2024 – The European Society for Medical Oncology is pleased to announce the ESMO Gastrointestinal Cancers Congress 2024, the scientific congress entirely dedicated to the presentation of advances and discussions around the prevention, diagnosis and management of malignancies of the gastrointestinal tract.
Lugano, Switzerland, 14 June 2024 – The European Society for Medical Oncology is pleased to announce the ESMO Gastrointestinal Cancers Congress 2024, the scientific congress entirely dedicated to the presentation of advances and discussions around the prevention, diagnosis and management of malignancies of the gastrointestinal tract.
The event will take place in Munich, Germany, between 26-29 June and will include a virtual component to give everyone the opportunity to attend.
The full congress programme is available online together with abstracts and late-breaking abstract titles, covering educational sessions on state-of-the-art treatment options, trending topics such as the early onset of GI malignancies and the application of precision medicine for better management of patients.
Below are some highlights helpful to easily navigate the programme:
- Phase-3 clinical trials with potential practice changing results in:
-
advanced gastric and gastroesophageal cancer (LBA3, LBA4)
-
rare GI cancers (211MO)
-
biliary cancer (279MO)
-
-
Facilitate the early detection of hepatocellular carcinoma through innovative approaches, including the use of artificial intelligence (165MO, 181P)
-
Novel insights in the role of precision medicine in GI cancer (session on Friday, 28 June, 11:15-12:45)
-
New data on the molecular characteristics of early onset of GI cancers (Session on Thursday, 27 June, 16:30-18:00, 80P, 132P, 139P, 140P, 291P, 365P)
-
The crucial role of multidisciplinary tumour boards to manage complex GI cancers cases and define the best treatment strategies for the patients (sessions on Wednesday, 26 June, 14:30-16:00, Thursday, 27 June, 8:30-9:30, Friday, 28 June, 8:30-10:00).
Keynote Lecture
-
“KRAS is not undruggable anymore” by Ryan B. Corcoran, 26 June, 13:30-14:15 CEST
-
“Immunotherapy for MSS-colorectal cancer: The last frontier” by Myriam Chalabi, 27 June, 9:45-10:15 CEST
-
“Gut onco-microbiome signatures” by Laurence Zitvogel, 28 June, 10:30-11:00 CEST
-
“Ten years of improvement in the treatment of liver cancer” by Stephen L. Chan, 29 June, 10:30-12:30 CEST
The results of 549 studies will be presented and published online as a supplement to Annals of Oncology.
Press conference
Ahead of the event, on the morning of Wednesday, 26 June, accredited press representatives will have the opportunity to listen to and ask questions to GI oncology experts during a press conference, reserved to accredited journalists. Further details will be released soon. In the meantime, please make sure to submit your request for accreditation before Tuesday, 25 June.
Press accreditation
ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities. To apply for press accreditation, please fill out the form available here. Requests for press accreditation should be sent by Tuesday, 25 June. Please be kindly informed that onsite press accreditation will not be possible.
Third Parties Media registration
Third Party Media representatives and Filming Crews not eligible as press must abide by the ESMO Policy on Media Activities Organised by Third Parties and can request a Third Parties Media badge through registration@esmo.org (cc media@esmo.org).
Further information
ESMO Press Office
press@esmo.org
Notes to editors
Please make sure to use the official name of the meeting in your reports: ESMO Gastrointestinal Cancers Congress 2024 and the official congress hashtag #ESMOGI24. Follow it to stay up to date and use it to take part in the conversation on X (Twitter), LinkedIn, Facebook, Instagram, YouTube.
About the European Society for Medical Oncology (ESMO)
Representing more than 35,000 oncology professionals from 172 countries worldwide, ESMO is a reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE. www.esmo.org
